Latest Earnings Results: Q3 '26
Estimated EPS
-$0.50
Reported EPS
-$0.40
Surprise
+20.79%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.40 up 24.53% YoY • Atea Pharmaceuticals believes existing resources, including $65M borrowed, will fund planned operations into mid-2028; based on current plans, it does not anticipate product sales revenue for the foreseeable future.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.44 | -- | -- | N/A |
Q3 '26 | -$0.50 | -$0.40 | 20.79% | BEAT |
Q2 '26 | -$0.56 | -$0.41 | 26.13% | BEAT |
Q1 '26 | -$0.56 | -$0.57 | -2.70% | MISSED |
Q4 '25 | -$0.49 | -$0.57 | -17.53% | MISSED |